APA (7th ed.) Citation

G, A., JK, S., J, T., G, F., V, K., & B, N. (2022). A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Melanoma research, 32(3), 183. https://doi.org/10.1097/CMR.0000000000000821

Chicago Style (17th ed.) Citation

G, Awada, Schwarze JK, Tijtgat J, Fasolino G, Kruse V, and Neyns B. "A Lead-in Safety Study Followed by a Phase 2 Clinical Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Advanced BRAFV600 Mutant Melanoma Patients Previously Treated with BRAF-/MEK-inhibitors and Immune Checkpoint Inhibitors." Melanoma Research 32, no. 3 (2022): 183. https://doi.org/10.1097/CMR.0000000000000821.

MLA (9th ed.) Citation

G, Awada, et al. "A Lead-in Safety Study Followed by a Phase 2 Clinical Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Advanced BRAFV600 Mutant Melanoma Patients Previously Treated with BRAF-/MEK-inhibitors and Immune Checkpoint Inhibitors." Melanoma Research, vol. 32, no. 3, 2022, p. 183, https://doi.org/10.1097/CMR.0000000000000821.